IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN

被引：0
|
作者：
Hiddemann, W. [1 ]
Barbui, A. M. [2 ]
Albendea, M. A. Canales [3 ]
Cannell, P. K. [4 ]
Collins, G. P. [5 ]
Duerig, J. [6 ]
Forstpointner, R. [1 ]
Herold, M. [7 ]
Hertzberg, M. [8 ]
Klanova, M. [9 ,10 ,11 ]
Radford, J. A. [12 ,13 ]
Tobinai, K. [14 ]
Burciu, A. [15 ]
Fingerle-Rowson, G. R. [11 ]
Nielsen, T. [11 ]
Wolbers, M. [16 ]
Marcus, R. E. [17 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Dept Med 3, Munich, Germany
[2] Azienda Osped Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy
[3] Hosp Univ la Paz, Dept Med, Madrid, Spain
[4] Fiona Stanley Hosp, Dept Haematol, Murdoch, WA, Australia
[5] Churchill Hosp, Oxford Canc & Haematol Ctr, Dept Clin Haematol, Oxford, England
[6] Univ Klinikum Essen, Med Fac Haematol, Essen, Germany
[7] HELIOS Klinikum Erfurt, Ctr Oncol, Erfurt, Germany
[8] Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia
[9] Charles Univ Prague, Fac Med 1, Gen Hosp, Prague, Czech Republic
[10] Charles Univ Prague, Inst Pathol Physiol, Prague, Czech Republic
[11] F Hoffmann La Roche Ltd, Pharma Dev Clin Oncol, Basel, Switzerland
[12] Univ Manchester, Manchester, Lancs, England
[13] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[14] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[15] F Hoffmann La Roche Ltd, Pharma Dev Safety & Risk Management, Basel, Switzerland
[16] F Hoffmann La Roche Ltd, Pharma Dev Biometr Biostat, Basel, Switzerland
[17] Kings Coll Hosp London, Dept Haematol, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S775
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [1] Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
    Hiddemann, Wolfgang
    Barbui, Anna Maria
    Canales, Miguel A.
    Cannell, Paul K.
    Collins, Graham P.
    Duerig, Jan
    Forstpointner, Roswitha
    Herold, Michael
    Hertzberg, Mark
    Klanova, Magdalena
    Radford, John
    Seymour, John F.
    Tobinai, Kensei
    Trotman, Judith
    Burciu, Alis
    Fingerle-Rowson, Gunter
    Wolbers, Marcel
    Nielsen, Tina
    Marcus, Robert E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2395 - +
  • [2] Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety (vol 36, pg 2395, 2018)
    Hiddemann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) : 2815 - 2815
  • [3] Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial
    Herold, Michael
    Hoster, Eva
    Janssens, Ann
    McCarthy, Helen
    Tedeschi, Alessandra
    Pocock, Chris
    Rosta, Andras
    Trneny, Marek
    Nielsen, Tina G.
    Knapp, Andrea
    Hiddemann, Wolfgang
    Marcus, Robert
    HEMASPHERE, 2022, 6 (03): : E699
  • [4] Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
    Andrew Davies
    Peter Trask
    Judit Demeter
    Axel Florschütz
    Mathias Hänel
    Tomohiro Kinoshita
    Ruth Pettengell
    Hang Quach
    Stephen Robinson
    Shalal Sadullah
    Juan-Manuel Sancho
    Miklos Udvardy
    Mathias Witzens-Harig
    Andrea Knapp
    Wenxin Liu
    Annals of Hematology, 2020, 99 : 2837 - 2846
  • [5] Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
    Davies, Andrew
    Trask, Peter
    Demeter, Judit
    Florschuetz, Axel
    Haenel, Mathias
    Kinoshita, Tomohiro
    Pettengell, Ruth
    Quach, Hang
    Robinson, Stephen
    Sadullah, Shalal
    Sancho, Juan-Manuel
    Udvardy, Miklos
    Witzens-Harig, Mathias
    Knapp, Andrea
    Liu, Wenxin
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2837 - 2846
  • [6] Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
    Townsend, William
    Buske, Christian
    Cartron, Guillaume
    Cunningham, David
    Dyer, Martin J. S.
    Gribben, John G.
    Zhang, Zilu
    Rufibach, Kaspar
    Nielsen, Tina
    Herold, Michael
    Hiddemann, Wolfgang
    Marcus, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
    Townsend, William
    Hiddemann, Wolfgang
    Buske, Christian
    Cartron, Guillaume
    Cunningham, David
    Dyer, Martin J. S.
    Gribben, John G.
    Phillips, Elizabeth H.
    Dreyling, Martin
    Seymour, John F.
    Grigg, Andrew
    Trotman, Judith
    Lin, Tong-Yu
    Hong, Xiao-Nan
    Kingbiel, Dirk
    Nielsen, Tina G.
    Knapp, Andrea
    Herold, Michael
    Marcus, Robert
    HEMASPHERE, 2023, 7 (07): : E919
  • [8] Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial
    Ohmachi, Ken
    Tobinai, Kensei
    Kinoshita, Tomohiro
    Ishikawa, Takayuki
    Hatake, Kiyohiko
    Ichikawa, Satoshi
    Ohmine, Ken
    Kamitsuji, Yuri
    Choi, Ilseung
    Chou, Takaaki
    Tsukasaki, Kunihiro
    Kumagai, Kyoya
    Taniwaki, Masafumi
    Uchida, Toshiki
    Kikukawa, Yoshitaka
    Kubo, Kohmei
    Mihara, Keichiro
    Tsukamoto, Norifumi
    Izutsu, Koji
    Yoshida, Isao
    Ishida, Fumihiro
    Usui, Noriko
    Iida, Shinsuke
    Murayama, Tohru
    Ueda, Eisuke
    Kuriki, Hiroshi
    Ando, Kiyoshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (05) : 499 - 509
  • [9] Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial
    Ken Ohmachi
    Kensei Tobinai
    Tomohiro Kinoshita
    Takayuki Ishikawa
    Kiyohiko Hatake
    Satoshi Ichikawa
    Ken Ohmine
    Yuri Kamitsuji
    Ilseung Choi
    Takaaki Chou
    Kunihiro Tsukasaki
    Kyoya Kumagai
    Masafumi Taniwaki
    Toshiki Uchida
    Yoshitaka Kikukawa
    Kohmei Kubo
    Keichiro Mihara
    Norifumi Tsukamoto
    Koji Izutsu
    Isao Yoshida
    Fumihiro Ishida
    Noriko Usui
    Shinsuke Iida
    Tohru Murayama
    Eisuke Ueda
    Hiroshi Kuriki
    Kiyoshi Ando
    International Journal of Hematology, 2018, 108 : 499 - 509
  • [10] Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients
    Pott, Christiane
    Hoster, Eva
    Kehden, Britta
    Unterhalt, Michael
    Herold, Michael
    van der Jagt, Richard
    Janssens, Ann
    Kneba, Michael
    Mayer, Jiri
    Pocock, Christopher
    Knapp, Andrea
    Danesi, Nathalie
    Nielsen, Tina
    Brown, Helen
    Mundt, Kirsten
    Marcus, Robert
    Hiddemann, Wolfgang
    BLOOD, 2018, 132
12345